Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial von Shcherbinin, Sergey, Evans, Cynthia D, Lu, Ming, Andersen, Scott W, Pontecorvo, Michael J, Willis, Brian A, Gueorguieva, Ivelina, Hauck, Paula M, Brooks, Dawn A, Mintun, Mark A, Sims, John R

Volltext

APOE ε4's impact on response to amyloid therapies in early symptomatic Alzheimer's disease: Analyses from multiple clinical trials von Evans, Cynthia D., Sparks, JonDavid, Andersen, Scott W., Brooks, Dawn A., Hauck, Paula M., Mintun, Mark A., Sims, John R.

Volltext

The Discovery, Preclinical, and Early Clinical Development of Potent and Selective GPR40 Agonists for the Treatment of Type 2 Diabetes Mellitus (LY2881835, LY2922083, and LY2922470... von Hamdouchi, Chafiq, Kahl, Steven D, Patel Lewis, Anjana, Cardona, Guemalli R, Zink, Richard W, Chen, Keyue, Eessalu, Thomas E, Ficorilli, James V, Marcelo, Marialuisa C, Otto, Keith A, Wilbur, Kelly L, Lineswala, Jayana P, Piper, Jared L, Coffey, D. Scott, Sweetana, Stephanie A, Haas, Joseph V, Brooks, Dawn A, Pratt, Edward J, Belin, Ruth M, Deeg, Mark A, Ma, Xiaosu, Cannady, Ellen A, Johnson, Jason T, Yumibe, Nathan P, Chen, Qi, Maiti, Pranab, Montrose-Rafizadeh, Chahrzad, Chen, Yanyun, Reifel Miller, Anne

Volltext

TRAILBLAZER-ALZ 4: Topline Study Results Directly Comparing Donanemab to Aducanumab on Amyloid Lowering in Early, Symptomatic Alzheimer's Disease von Salloway, Stephen, Lee, Elly, Papka, Michelle, Pain, Andrew, Oru, Ena, Ferguson, Margaret B., Wang, Hong, Case, Michael, Lu, Ming, Collins, Emily C, Brooks, Dawn A., Sims, John

Volltext

Application of the Dakin−West Reaction for the Synthesis of Oxazole-Containing Dual PPARα/γ Agonists von Godfrey, Alexander G, Brooks, Dawn A, Hay, Lynne A, Peters, Mary, McCarthy, James R, Mitchell, David

Volltext

A tailored therapy for the metabolic syndrome: The dual peroxisome proliferator-activated receptor-α/γ agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia wh... von ETGEN, Garret J, OLDHAM, Brian A, SHUKER, Anthony J, RITO, Christopher J, MCCARTHY, James R, ARDECKY, Robert J, TYHONAS, John S, DANA, Sharon L, BILAKOVICS, James M, PATERNITI, James R, OGILVIE, Kathleen M, SHA LIU, JOHNSON, William T, KAUFFMAN, Raymond F, BRODERICK, Carol L, MONTROSE, Chahrzad R, BROZINICK, Joseph T, MISENER, Elizabeth A, BEAN, James S, BENSCH, William R, BROOKS, Dawn A

Volltext

TRAILBLAZER-ALZ 2: A Phase 3 Study to Assess Safety and Efficacy of Donanemab in Early Symptomatic Alzheimer’s Disease (P18-3.005) von Zimmer, Jennifer, Solomon, Paul, Evans, Cynthia D., Lu, Ming, Sims, John R., Brooks, Dawn A., Mintun, Mark A.

Volltext

Design and Synthesis of 2-Methyl-2-{4-[2-(5-methyl-2-aryloxazol- 4-yl)ethoxy]phenoxy}propionic Acids:  A New Class of Dual PPARα/γ Agonists von Brooks, Dawn A, Etgen, Garret J, Rito, Christopher J, Shuker, Anthony J, Dominianni, Samuel J, Warshawsky, Alan M, Ardecky, Robert, Paterniti, James R, Tyhonas, John, Karanewsky, Donald S, Kauffman, Raymond F, Broderick, Carol L, Oldham, Brian A, Montrose-Rafizadeh, Chahzrad, Winneroski, Leonard L, Faul, Margaret M, McCarthy, James R

Volltext

Amyloid re‐accumulation after donanemab treatment: summary from 3 interventional trials von Shcherbinin, Sergey, Gueorguieva, Ivelina, Cheng, Yun‐Ju, Evans, Cynthia D., Case, Michael G., Chidambaram, Swathi, Collins, Emily C., Brooks, Dawn A., Sims, John R., Lu, Ming

Volltext

TRAILBLAZER‐ALZ 4: Directly comparing donanemab to aducanumab on amyloid lowering in early, symptomatic Alzheimer’s disease ‐ Results from 12‐months von Pain, Andrew, Ferguson, Margaret B, Wang, Hong, Salloway, Stephen, Lee, Elly, Papka, Michelle, Hu, Haoyan B, Lu, Ming, Oru, Ena B, Collins, Emily C., Brooks, Dawn A., Sims, John R.

Volltext

Developing Topics von Pain, Andrew, Ferguson, Margaret B, Wang, Hong, Salloway, Stephen, Lee, Elly, Papka, Michelle, Hu, Haoyan B, Lu, Ming, Oru, Ena B, Collins, Emily C, Brooks, Dawn A, Sims, John R

Volltext

Donanemab in Early Symptomatic Alzheimer’s Disease: Efficacy and Safety in TRAILBLAZER‐ALZ 2, a Phase 3 Randomized Clinical Trial von Mintun, Mark, Ritchie, Craig W, Solomon, Paul, Sims, John R., Salloway, Stephen, Hansson, Oskar, Apostolova, Liana G., Zimmer, Jennifer A., Evans, Cynthia D., Lu, Ming, Ardayfio, Paul A, Sparks, JonDavid, Wessels, Alette M, Shcherbinin, Sergey, Wang, Hong, Nery, Emel Serap Monkul, Collins, Emily C., Dennehy, Ellen B, Brooks, Dawn A., Skovronsky, Daniel M.

Volltext

TRAILBLAZER‐ALZ Study: Dynamics of amyloid reduction after donanemab treatment von Shcherbinin, Sergey, Andersen, Scott W., Evans, Cynthia Duggan, Lo, Albert C., Lu, Ming, Navitsky, Michael, Collins, Emily C, Sims, John R., Brooks, Dawn A., Mintun, Mark A

Volltext

Conversion of human-selective PPARα agonists to human/mouse dual agonists: a molecular modeling analysis von Wang, Minmin, Winneroski, Leonard L., Ardecky, Robert J., Babine, Robert E., Brooks, Dawn A., Etgen, Garret J., Hutchison, Darrell R., Kauffman, Raymond F., Kunkel, Aaron, Mais, Dale E., Montrose-Rafizadeh, Chahrzad, Ogilvie, Kathleen M., Oldham, Brian A., Peters, Mary K., Rito, Christopher J., Rungta, Deepa K., Tripp, Allie E., Wilson, Sarah B., Xu, Yanping, Zink, Richard W., McCarthy, James R.

Volltext

Donanemabの臨床開発とバイオマーカー：第II相試験におけるアミロイドプラーク量の変化 von 佐藤, 祥一郎

Volltext

For director-at-large: Dawn A. Brooks von Dawn A. Brooks

Volltext

A Tailored Therapy for the Metabolic Syndrome von Etgen, Garret J., Oldham, Brian A., Johnson, William T., Broderick, Carol L., Montrose, Chahrzad R., Brozinick, Joseph T., Misener, Elizabeth A., Bean, James S., Bensch, William R., Brooks, Dawn A., Shuker, Anthony J., Rito, Christopher J., McCarthy, James R., Ardecky, Robert J., Tyhonas, John S., Dana, Sharon L., Bilakovics, James M., Paterniti, James R., Ogilvie, Kathleen M., Liu, Sha, Kauffman, Raymond F.

Volltext

AOD1-5. 早期アルツハイマー病患者におけるドナネマブとアデュカヌマブのアミロイド除去効果に関する直接比較 von 佐藤祥一郎, Stephen Salloway, Andrew Pain, Margaret B. Ferguson, Hong Wang, Elly Lee, Michelle Papka, Haoyan Hu, Ming Lu, Ena Oru, Emily C. Collins, Dawn A. Brooks, John R. Sims

Volltext

Studies of mild dehydrogenations in heterocyclic systems von Williams, David R., Lowder, Patrick D., Gu, Yu-Gui, Brooks, Dawn A.

Volltext

Total Synthesis of (−)-Hennoxazole A von Williams, David R., Brooks, Dawn A., Berliner, Martin A.

Volltext